Revelation Biosciences Inc (REVB)
Revelation Biosciences, Inc. is a clinical-stage life science company focused on modulating the innate immune response, with an emphasis on rebalancing inflammation to support health outcomes. Its lead candidate, Gemini, is based on a proprietary PHAD formulation and is designed to act as a Toll-like receptor 4 (TLR4) agonist. The company is also developing product candidates for inflammatory and kidney-related conditions, including GEM-AKI for the prevention and treatment of acute kidney injury and GEM-CKD for chronic kidney disease. Incorporated in 2019 and based in San Diego, California, the company changed its name from Petra Acquisition, Inc. in January 2022. Revelation Biosciences trades on NASDAQ as common stock under the ticker REVB.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-REVB
|
$1.67
|
42.9% Upside
|
Undervalued
|
$19.25 1,545.3% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-0.2x
|
0.4x
|
—
|
4.534 M
|
-8.782 M
|
14.3%
|
87.9%
|
-0.4
|
—
|
40.7%
|
